Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Neurodegenerative Diseases Report 2017 - Protein Misfolding Targets & Neuromodulators Dominate the First-in-Class Pipeline - Research and Markets

Research and Markets
Posted on: 18 Dec 17

The "Frontier Pharma: Neurodegenerative Diseases - Protein Misfolding Targets and Neuromodulators Dominate the First-in-Class Pipeline and Lead the Way as Potential Disease-Modifying Therapies in AD and PD" drug pipelines has been added to Research and Markets' offering.

Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are characterized by neuronal death within the brain and/or central nervous system (CNS), leading to progressive decline in functional neurological capacities. It has a devastating effect on quality of life and independence, often requiring full-time care during the later disease stages. Conditions within the therapy area are diverse, and exhibit specific pathophysiologies and etiologies, while affecting people of all ages. This report examines the entire neurodegenerative disease therapy area, with a particular focus on the three most prevalent neurodegenerative disorders: Alzheimer's disease (AD), Parkinson's disease (PD) and multiple sclerosis (MS).

AD and PD represent the most pressing challenges within the disease cluster, due to rapidly increasing prevalence driven by aging populations. Both AD and PD remain ineffectively treated despite substantial investment into R&D by pharmaceutical companies, due to high clinical trial failure rates. As a result there are no disease-modifying therapies for these two indications, with available treatments able to provide only marginal symptomatic relief. MS, the autoimmune disease of the CNS, contrasts with the rest of this cluster, as it affects a different population demographic, and has a lucrative pharmacological market following breakthrough success in the past decade.

Key Topics Covered:

1 Table of Contents

2 Executive Summary

3 The Case for Innovation

4 Clinical and Commercial Landscape

5 Assessment of Pipeline Product Innovation

6 Signaling Network and Innovation Alignment within Neurodegenerative Disease

7 First-in-Class Target and Pipeline Program Evaluation

8 Strategic Consolidations

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3qb8bc/frontier_pharma

View source version on businesswire.com: http://www.businesswire.com/news/home/20171218005464/en/

Business Wire
www.businesswire.com

Last updated on: 18/12/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.